TMCI vs. SGHT, ORGO, ANGO, BVS, SIBN, MDXG, ATRC, SINT, AORT, and CATX
Should you be buying Treace Medical Concepts stock or one of its competitors? The main competitors of Treace Medical Concepts include Sight Sciences (SGHT), Organogenesis (ORGO), AngioDynamics (ANGO), Bioventus (BVS), SI-BONE (SIBN), MiMedx Group (MDXG), AtriCure (ATRC), Sintx Technologies (SINT), Artivion (AORT), and Perspective Therapeutics (CATX). These companies are all part of the "medical" sector.
Sight Sciences (NASDAQ:SGHT) and Treace Medical Concepts (NASDAQ:TMCI) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, media sentiment, community ranking, earnings, institutional ownership, profitability, risk, dividends and analyst recommendations.
Treace Medical Concepts received 9 more outperform votes than Sight Sciences when rated by MarketBeat users. Likewise, 53.33% of users gave Treace Medical Concepts an outperform vote while only 31.91% of users gave Sight Sciences an outperform vote.
Sight Sciences presently has a consensus price target of $4.70, indicating a potential downside of 28.35%. Treace Medical Concepts has a consensus price target of $12.21, indicating a potential upside of 107.73%. Given Sight Sciences' higher possible upside, analysts clearly believe Treace Medical Concepts is more favorable than Sight Sciences.
Treace Medical Concepts has higher revenue and earnings than Sight Sciences. Treace Medical Concepts is trading at a lower price-to-earnings ratio than Sight Sciences, indicating that it is currently the more affordable of the two stocks.
55.5% of Sight Sciences shares are owned by institutional investors. Comparatively, 84.1% of Treace Medical Concepts shares are owned by institutional investors. 28.9% of Sight Sciences shares are owned by insiders. Comparatively, 24.4% of Treace Medical Concepts shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Sight Sciences has a beta of 2.73, suggesting that its stock price is 173% more volatile than the S&P 500. Comparatively, Treace Medical Concepts has a beta of 0.37, suggesting that its stock price is 63% less volatile than the S&P 500.
Treace Medical Concepts has a net margin of -27.93% compared to Treace Medical Concepts' net margin of -67.18%. Sight Sciences' return on equity of -39.66% beat Treace Medical Concepts' return on equity.
In the previous week, Sight Sciences and Sight Sciences both had 9 articles in the media. Sight Sciences' average media sentiment score of 1.09 beat Treace Medical Concepts' score of 0.64 indicating that Treace Medical Concepts is being referred to more favorably in the news media.
Summary
Treace Medical Concepts beats Sight Sciences on 11 of the 16 factors compared between the two stocks.
Get Treace Medical Concepts News Delivered to You Automatically
Sign up to receive the latest news and ratings for TMCI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TMCI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Treace Medical Concepts Competitors List
Related Companies and Tools
